For the year ending 2025-12-31, PYXS made $13,858K in revenue. -$79,738K in net income. Net profit margin of -575.39%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 13,858 | |||
| Cost of revenues | 2,388 | |||
| Research and development | 73,696 | |||
| General and administrative | 22,194 | |||
| Total costs and operating expenses | 98,278 | |||
| Loss from operations | -84,420 | |||
| Interest and investment income, net | 3,610 | |||
| Sublease income | 2,575 | |||
| Total other income, net | 6,185 | |||
| Income (loss) from continuing operations before income taxes, noncontrolling interest, total | -78,235 | |||
| Income tax expense (benefit) | 1,386 | |||
| Net loss | -79,621 | |||
| Net unrealized (loss) gain on marketable debt securities | -117 | |||
| Other comprehensive (loss) income | -117 | |||
| Comprehensive loss | -79,738 | |||
| Basic EPS | -1.28 | |||
| Diluted EPS | -1.28 | |||
| Basic Average Shares | 62,143,166 | |||
| Diluted Average Shares | 62,143,166 | |||
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)